The increase immunosuppression in our transplant population has led to an unacceptable rate
of patients at risk for BK virus nephropathy. Reducing induction immunosuppression by
switching from Thymoglobulin to Simulect will reduce the incidence of serum positivity for
BK by PCR.
Our standard of care has been changed from Thymoglobulin to Simulect and now patients were
enrolled in this observational trial to gather data on their outcomes related to BK viremia
and rejection rates. Two groups of patients were compared.
Retrospective (historical or control) group of subjects: patients who had received a kidney
transplant and were inducted with Thymoglobulin prior to study initiation.
Prospective group of subjects: patients who is scheduled to receive kidney transplant and
will be inducted with Simulect (Basiliximab).
Inductions in both groups was/is Standard of Care at a time of treatment.
- De novo transplant
- Aged 18-75
- Serious medical condition which, in the opinion of the Principal Investigator, might
interfere with the subject's ability to successfully complete the protocol.
- Any medical condition which, in the opinion of the Principal Investigator, might
compromise the safety of the subject in participating in the protocol